Swedish mutation

Swedish mutation refers to a rare genetic mutation in the amyloid precursor protein (APP) gene that causes early-onset familial Alzheimer's disease (EOFAD). This mutation is one of the most well-known and widely studied genetic variations associated with Alzheimer's disease, and it has played a significant role in shaping modern Alzheimer's disease research and therapeutic strategies.

History

The Swedish mutation was identified in 1992 by Dr. Michael Mullan and Dr. Fiona Crawford at the University of South Florida, using DNA samples provided by a team of Swedish researchers led by Dr. Lars Lannfelt. The mutation was discovered in two related Swedish families with a history of early-onset dementia.

This specific mutation leads to the development of Alzheimer's disease symptoms in affected individuals during their early 50s. As an autosomal dominant condition, each child of an affected individual has a 50% chance of inheriting the mutation. Despite its importance, the mutation is extremely rare and has only been documented in these two Swedish families; it has not been found in the general population elsewhere.

Genetics

The mutation involves a double missense mutation (KM670/671NL) in the gene encoding amyloid precursor protein (APP). This gene, located on chromosome 21, encodes a transmembrane protein that is cleaved by enzymes to produce beta-amyloid peptides.

In individuals with the Swedish mutation, abnormal processing of APP by the enzyme beta-secretase occurs within the secretory pathway, resulting in increased production of the neurotoxic peptide amyloid beta (Aβ), especially the Aβ40 and Aβ42 isoforms. These peptides aggregate and form amyloid plaques—a hallmark of Alzheimer's pathology.

Significance in Research

Before the discovery of the Swedish mutation, the role of amyloid plaques in Alzheimer's disease was widely debated. Some researchers believed that amyloid deposition was a secondary or terminal event ("tombstone") rather than a causative factor.

However, the finding that this single mutation in the APP gene was both necessary and sufficient to cause Alzheimer's disease in these families provided compelling evidence supporting the amyloid hypothesis—the theory that accumulation of amyloid beta is a primary event in the disease process.

The discovery contributed to:

• Validating APP and amyloid beta as targets for drug development.
• Supporting the use of transgenic animal models for studying Alzheimer's disease.
• Accelerating efforts to develop disease-modifying treatments aimed at reducing amyloid burden in the brain.

Transgenic Models

The mutation was introduced into mice to develop transgenic models of Alzheimer's disease, such as the Tg2576 mouse. These mice express human APP with the Swedish mutation and begin to develop amyloid plaques at around 13 months of age, mimicking key features of the human disease.

These models are widely used to:

• Investigate the role of amyloid pathology in neurodegeneration.
• Study cognitive decline and memory loss.
• Evaluate potential Alzheimer's disease treatments including immunotherapy, beta-secretase inhibitors, and gamma-secretase inhibitors.

Pathophysiology

The mutation leads to enhanced cleavage of APP by beta-secretase, bypassing the normal alpha-secretase pathway. This results in an overproduction of amyloid beta peptides, particularly Aβ42, which is more prone to aggregation and is neurotoxic. Amyloid plaques interfere with synaptic function, promote inflammation, and contribute to neuronal cell death.

Inheritance

The Swedish mutation follows an autosomal dominant inheritance pattern. Affected individuals usually present with symptoms of Alzheimer's disease between ages 50 and 60, including:

• Progressive memory loss
• Cognitive decline
• Personality changes
• Loss of executive function

Impact on Therapeutics

Because of the Swedish mutation's direct role in increasing amyloid beta production, it has become a key target in developing:

• Monoclonal antibodies against amyloid (e.g., aducanumab)
• Small molecule inhibitors of beta-secretase (BACE)
• APP-processing modulators

See also

• Amyloid hypothesis
• Early-onset Alzheimer's disease
• Familial Alzheimer's disease
• Alzheimer's disease
• Tg2576 mouse
• Beta-amyloid

External links

• Alzheimer's Association
• OMIM entry on APP gene

   This article is a  stub. You can help WikiMD by expanding it!